Add to balance / Manage account | User: | Log out |
Prospect News home > News index > List of issuers G > Headlines for Genentech Inc. > News item |
Merrill reiterates Genentech at buy
Genentech Inc. was reiterated at a buy by Merrill Lynch analyst Eric Ende on news that the third-party prescription data provider NDC restated Avastin, Herceptin and Rituxan sales data below previously reported amounts. As a result, Genentech's cancer drugs could meaningfully miss consensus and Merrill's third-quarter estimates. Shares of the South San Francisco, Calif.-based biotherapeutic company were down $1.48, or 1.74%, at $82.40. (NYSE: DNA)
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.